AUCTORES
Globalize your Research
Review Article | DOI: https://doi.org/10.31579/2637-8892/214
1 Lecturer, Department of Psychiatric Nursing, College of Nursing, Pt. B.D. Sharma University of Health Sciences, Rohtak 124001 India.
2 Nursing Advisor, Dte. GHS, Ministry of Health and Family Welfare, New Delhi, India.
*Corresponding Author: Jaison Joseph, Lecturer, Department of Psychiatric Nursing, College of Nursing, Pt. B.D. Sharma University of Health Sciences, Rohtak 124001 India.
Citation: Joseph J., Deepika C. Khakha, (2023), Disulfiram Therapy for alcohol dependence in the Indian Context: - What Does the Literature Say?, Psychology and Mental Health Care, 7(1): DOI:10.31579/2637-8892/214
Copyright: © 2023, Jaison Joseph. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Received: 14 April 2023 | Accepted: 01 May 2023 | Published: 08 May 2023
Keywords: disulfiram; alcohol; India
Disulfiram is relatively the oldest molecule and one of the current medications for treating alcohol dependence. It is found to be a cheap prophylactic agent for treating alcohol dependence for the past many years. Many factors influence acceptance and adherence to disulfiram treatment based on various contexts. Interestingly, physical and psychiatric complications related to disulfiram treatment were reported as a predictor for poor drug adherence. There is convincing evidence to suggest that supervised disulfiram still has a major role in alcohol de-addiction treatment. Further, it is worth noting that disulfiram is the cheapest pharmacoprophylactic drug for alcohol dependence putting its importance on people living in low and middle-income countries. The present review elucidates the status of disulfiram therapy for alcohol dependence in the Indian context.
The burden and problems due to alcohol dependence are well documented at the global level. The pharmacological treatment for alcohol dependence is growing with empirical trials of both older and novel agents. Disulfiram is relatively the oldest molecule and one of the current medications for treating alcohol dependence. It is found to be a cheap prophylactic agent for treating alcohol dependence for the past many years [1]. Disulfiram is usually prescribed for middle-aged male alcohol-dependent subjects with somewhat intact social stability and supervisory system after obtaining written informed consent. The common Disulfiram ethanol reactions (DER) are flushing, sweating, nausea, vomiting, palpitations, dyspnoea, tremors, confusion, restlessness, drowsiness, and hypotension which may develop within 5-15 minutes of alcohol intake. The general side effects in the absence of alcohol consumption include headache, general weakness, and dizziness [2]. The following medications must be avoided while on disulfiram treatment: - alcohol-containing syrups, sedatives such as diazepam, anti-diarrhoeal such as metrogyl, cardiac medication such as digitalis, anti-epileptic such as phenobarbitones, anti-tubercular medications such as rifampicin, isoniazid, anti-coagulants such as warfarin, anti-depressants such as depsonil. Further, avoid the following food and cosmetic items during the disulfiram therapy as it may lead to DER (sausages, shaving lotions, vinegar, etc) [3].
Many factors influence acceptance and adherence to disulfiram treatment based on various contexts. Interestingly, physical and psychiatric complications related to disulfiram treatment were reported as a predictor for poor drug adherence. Furthermore, researchers pointed out that the adverse effects could be dose-specific inculcating the need for regular follow-up for patients undergoing this therapy [4]. Many studies have been conducted for the efficacy and status of disulfiram in the alcohol de-addiction setting. There is convincing evidence to suggest that supervised disulfiram still has a major role in alcohol de-addiction treatment. Further, it is worth noting that disulfiram is the cheapest pharmacoprophylactic drug for alcohol dependence putting its importance in people living in low and middle-income countries [5]. The present review elucidates the status of disulfiram therapy for alcohol dependence in the Indian Context.
Disulfiram for preventing alcohol relapse in the Indian Context: - Evaluation of Efficacy trials & observational studies
A series of open-label trials compared the efficacy of disulfiram with acamprosate, naltrexone, and topiramate among hundred alcohol-dependent men attending a routine clinical practice in India.
Findings of these studies have the opinion that eighty-eight percent of patients on DSF remained abstinent compared to 46% with acamprosate [6]. Furthermore, eighty-six percent of the patients remained abstinent throughout the study with disulfiram compared to 44% with naltrexone [7]. In addition, they noted that 90% of the DSF patients remained abstinent as compared to 56% with topiramate [8]. All these studies are published in the year 2004-2008 and no other clinical trials and the follow-up period ranged from 9 -12 months. The findings demonstrated that disulfiram is superior for preventing relapse in the Indian alcohol de-addiction setting. From these findings, it can be assumed that this 'old-fashioned drug' appears to be a cost-effective molecule in the relapse prevention of alcohol dependence as compared to other anti-craving agents. Prasad S et al. (2000) reported that 81.7% (58/71) of outpatient patients attending a tertiary care centre from South India maintained total alcohol abstinence during follow-up at six months of disulfiram treatment [9]. In an observational study, Sidana A (2007) reported superior alcohol abstinence rates for disulfiram as compared to other pharmacological agents during 6-12 months among subjects in the Northern Indian setting.
Disulfiram Ethanol Reactions in India: - What Does the literature say?
Murthy KK (1997) reported the occurrence of mood disorder among 6 of 52 patients treated for alcohol dependence syndrome with a dose of 500 mg/day of disulfiram treatment [10]. An observational study by Sreenivasan and his colleagues (1994) evaluated 158 outpatients on daily oral disulfiram (250 mg/day) and revealed that 7 subjects experienced psychosis during the follow-up period [11]. Strikingly, a study from South India (Palatty, 2011) reported 76.5
Clearly Auctoresonline and particularly Psychology and Mental Health Care Journal is dedicated to improving health care services for individuals and populations. The editorial boards' ability to efficiently recognize and share the global importance of health literacy with a variety of stakeholders. Auctoresonline publishing platform can be used to facilitate of optimal client-based services and should be added to health care professionals' repertoire of evidence-based health care resources.
